Comments on: Measuring Success in the Biotech World http://www.xconomy.com/seattle/2009/04/28/measuring-success-in-the-biotech-world/ Business + Technology in the Exponential Economy Sat, 11 Feb 2012 01:49:51 +0000 hourly 1 http://wordpress.org/?v=3.0.4 By: PaulH http://www.xconomy.com/seattle/2009/04/28/measuring-success-in-the-biotech-world/comment-page-1/#comment-59381 PaulH Thu, 21 May 2009 13:02:10 +0000 http://www.xconomy.com/?p=22011#comment-59381 Good article. The only area that is missing is a discussion on access - making a needed treatment cost effective to both the maker and user. Relative to "me toos", these should be purer drugs and should lead to less side effects and interactions than the original. As more of the population is on multiple drugs, this becomes more important and utlimately benefits the user. Good article.
The only area that is missing is a discussion on access – making a needed treatment cost effective to both the maker and user.
Relative to “me toos”, these should be purer drugs and should lead to less side effects and interactions than the original. As more of the population is on multiple drugs, this becomes more important and utlimately benefits the user.

]]> By: CMCguy http://www.xconomy.com/seattle/2009/04/28/measuring-success-in-the-biotech-world/comment-page-1/#comment-55324 CMCguy Tue, 28 Apr 2009 23:16:42 +0000 http://www.xconomy.com/?p=22011#comment-55324 Because drug development takes combination of so many disciplines, many of which you well highlight, the best outcome is for something that achieves success across all/most those perspectives. At the same time majority of people doing the work have to be content with small victories because the full blown accomplishments are rare. I disagree with indicated approach to "punish" "me-toos" as first frequently when a program was initiated there was nothing directly to duplicate (and once become aware of competition that is ahead of you the investment so high that its too costly but to carry on). Occasionally companies will work on "well-trodden" areas but usually only because do believe have something new and/or what is out there has serve shortcomings. Secondly me toos can at times be benefit for portion of patients where other drug do not work/have bad tolerance (drugs rarely one size fits all). Finally, such products provides some stability/source of funds as the profits from me toos do get put back into R&D so will promote innovation in different areas. Because drug development takes combination of so many disciplines, many of which you well highlight, the best outcome is for something that achieves success across all/most those perspectives. At the same time majority of people doing the work have to be content with small victories because the full blown accomplishments are rare.

I disagree with indicated approach to “punish” “me-toos” as first frequently when a program was initiated there was nothing directly to duplicate (and once become aware of competition that is ahead of you the investment so high that its too costly but to carry on). Occasionally companies will work on “well-trodden” areas but usually only because do believe have something new and/or what is out there has serve shortcomings. Secondly me toos can at times be benefit for portion of patients where other drug do not work/have bad tolerance (drugs rarely one size fits all). Finally, such products provides some stability/source of funds as the profits from me toos do get put back into R&D so will promote innovation in different areas.

]]> By: Bob Busch http://www.xconomy.com/seattle/2009/04/28/measuring-success-in-the-biotech-world/comment-page-1/#comment-55238 Bob Busch Tue, 28 Apr 2009 16:17:09 +0000 http://www.xconomy.com/?p=22011#comment-55238 I am a 20 year veteran of the pharmaceutical industry. This is a great article, in my opinion. It covers a lot of ground and is objective. The failure rate for start-up drug companies is very high. I don't think the public really understands that. I am a 20 year veteran of the pharmaceutical industry. This is a great article, in my opinion. It covers a lot of ground and is objective. The failure rate for start-up drug companies is very high. I don’t think the public really understands that.

]]>